Compugen Expands Proteomics Product Line; Introduces the Z4000 System for Management and Analysis of Large Scale 2-D Gel Experiments.
SANTA CLARA, Calif.--(BW HealthWire)--Feb. 26, 2002
Compugen Ltd. (Nasdaq:CGEN) announced today at the Genome Tri-Conference, the release of Z4000(TM), its fully automated system for accurately designing, analyzing, and controlling large scale experiments of proteins as they appear on 2-D gels (a common tool for comparative analysis of protein expression).
This product launch marks a significant advancement in the management and image analysis of large-scale protein experiments, which previously were time consuming and relied on significant hardware power. Using advanced computational technologies, Z4000 enables the fast and accurate comparison and organization of multidimensional gel collections.
2-D gel electrophoresis is currently the method of choice for separating complex mixtures of proteins, the first step in the typical proteomics research workflow. Large-scale 2-D gel experiments are used to enable the study of multiple proteomes and allow for higher accuracy through repeat runs of gels sharing common conditions. Large-scale studies, however, typically consist of hundreds to thousands of gels, and it is impractical to analyze the vast numbers of gel images using traditional computer programs.
Z4000 addresses this limitation by managing and automating the analysis process of large-scale 2-D gel experiments through the use of proprietary algorithms for both gel comparisons and the computation of differential expression of multidimensional gel collections. In doing so, the Z4000 system offers a solution to a common bottleneck imposed by constraints of time and computational resources for scientists undertaking large scale studies. The software's strong computational engine enables the automated analysis of more than 50 gels per hour on a standard personal computer. Z4000 allows researchers to both design and alter the design of the experiment, as well as control its progress and accurately analyze large sets of gels. It employs advanced query tools that extract meaningful, precise and statistically robust data in an organized manner, while retaining a simple and intuitive user interface.
In October 2000, Compugen introduced Z3, its award-winning state-of-the-art solution for image analysis of 2-D gels, which already has more than 100 installations at leading pharmaceutical and biotechnology companies and research institutions worldwide. The Z4000 product now being introduced is based on the same computational engine and superior modeling technologies as Z3.
Erez Chimovits, President of the BioApplications Division of Compugen, stated, "Through automation and advanced computational modeling, Z4000 enables the comprehensive analysis of experiments with hundreds to thousands of gels -- a process that was practically impossible until now. We are delighted to be able to provide researchers with the capability to quickly and accurately identify relevant proteins that differentiate disease states, in large-scale protein gel experiments. Such proteins are likely candidates for therapeutic targets and diagnostic markers."
Compugen (Nasdaq:CGEN) is a leader in merging computational technologies with biology and medicine to enhance drug discovery and development. The Company's innovative predictive biology technologies support two complementary product development and commercialization divisions. Compugen's BioApplications division offers high value products and services that enable and enhance the discovery and functional analysis of genes, proteins and cell processes. Compugen's Novel Genomics division is developing human therapeutic and diagnostic products based on target genes, proteins and other intellectual property discovered through the Company's innovative research activities. For additional information, please visit Compugen's Corporate Web site at http://www.cgen.com/ and the Company's Internet research engine for molecular biologists, www.LabOnWeb.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's Registration Statement on Form F-1 and annual report filed with the Securities and Exchange Commission.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 26, 2002|
|Previous Article:||Cahners In-Stat/MDR Announces IBM and MIPS as Recipients of Microprocessor Report's Analysts' Choice Awards.|
|Next Article:||Logistics Management Resources Completes Acquisition of Interstate University Inc.|